Best Thymalfasin powder Peptides GMP Factory

Thymalfasin powder

Thymalfasin powder

Other names:Zadaxin,Thymosin alpha 1,alpha1-Thymosin,Thymosin-alpha-1,alpha1-Thymosin Thymalfasin,CCRIS 7700

Raw Thymalfasin peptide is an amino acid used to treat hepatitis B. It is a synthetically produced 28-amino acid peptide, but was originally isolated from thymosin fraction 5, an extract containing a variety of immunoactive peptides. In vitro studies have shown that Thymalfasin can affect the generation and maturation of T cells, stimulate the production of Th1 cytokines (such as interferon gamma and interleukin 2), and activate natural killer cell-mediated cytotoxicity

Production capacity: Provide customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Thymalfasin Peptide dosage calculator

Referenced Citations

[1]Thymalfasin: an immune system enhancer for the treatment of liver disease.Sjogren MH.J Gastroenterol Hepatol. 2004 Dec;19 Suppl 6:S69-72. doi: 10.1111/j.1440-1746.2004.03635.x. 

[2] Mutchnick, M.G., Lindsay, K.L., Schiff, E.R., Cummings, G.D., and H.D. Appelman (1995) Thymosin alpha 1 treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlled double blind study Gastroenterology.

[3]Thymalfasin for the treatment of chronic hepatitis C infection.Rustgi VK.Expert Rev Anti Infect Ther. 2005 Dec;3(6):885-92. doi: 10.1586/14787210.3.6.885.

[4] Salvati, F, et al., Combined treatment with thymosin alpha 1 and low dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Research 1996

[5]Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation.

[6]Advances in researches on the immune dysregulation and therapy of severe acute pancreatitis.Zhang XP, Chen HQ, Liu F, ZhangJ.

[7]Lopez, M, et al., Biochemotherapy with thymosin alpha 1, inteluken-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Annals of Oncology 1994

[8]Garaci E (September 2007). “Thymosin alpha1: a historical overview”. Ann. N. Y. Acad. Sci. 1112: 14–20.doi:nwiley.com.PMID 17567941. S2CID 222082988

[9]Wu X, Jia J, You H (2015). Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opinion on Biological Therapy. 15: 129– doi:10.1517/14712598.2015.1007948. PMID 25640173

[10]Relationship between the degree of severe acute pancreatitis and patient immunity.Shen Y, Deng X, Xu N, Li Y, Miao B, Cui N.

[11] Immunomodulatory therapies for acute pancreatitis.Li J, Yang WJ, Huang LM, Tang CW.

[12]Stefanini, G.F., et al., Alpha-1 thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience Hepatogastroenterology, 1988.

[13]Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review.Mehta Y, Dixit SB, Zirpe K, Sud R, Gopal PB, Koul PA, Mishra VK, Ansari AS, Chamle VS.

[14] “Human PubMed Reference:”. National Center for Biotechnology Information, U.S. National Library of Medicine.

[15]Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.Tsai YS, Jou YC, Tung CL, Lin CT, Shen CH, Chen SY, Tsai HT, Lai CL, Wu CL, Tzai TS

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

1.Gregorio Benitez

Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI, USA 

2.Cynthia W. Tuthill

LionHeart Consulting, St Helena, CA, USA

3.Xochitl García Samper

Hospital Adolfo López Mateos, México DF; 4. Centro Médico La Raza, México DF.

4.Han Bai

The MED-X Institute, The First Affiliated Hospital of Xi’an Jiaotong University, Building 21, Western China Science and Technology Innovation Harbor, Xi’an 710000, China

5.Olivia Manusama

Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. peptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.